Abstract #2208

Do gadolinium-based contrast agents alter 23Na T1 relaxivity in glioma?

Frank Riemer¹, Mary A McLean², Fulvio Zaccagna¹, James T Grist¹, Rolf F Schulte³, Joshua Kaggie¹, Colin Watts⁴, Stephen J Price⁴, Martin J Graves¹, and Ferdia A Gallagher¹

¹Department of Radiology, University of Cambridge, Cambridge, United Kingdom, ²Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom, ³GE Global Research, Munich, Germany, ⁴Neurosurgery Division, Dept. of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom

Incomplete fluid suppression on fluid-attenuated inversion-recovery ²³Na-MRI (IR-²³Na-MRI) was observed in three patients undergoing IR-²³Na-MRI after gadolinium contrast injection, as part of a brain tumour imaging study. To evaluate this, ²³Na-MRI T₁ maps were acquired before and after injection of a gadolinium-based contrast agent on a grade IV glioma (GBM) patient, which showed a statistically significant change of ²³Na-MRI T₁ within the peritumoral oedema (p=0.0095). Gadolinium contrast-enhanced ²³Na-MRI could potentially add further applications for sodium imaging and probe tumour tissue structure in new ways to investigate proliferation and treatment response.

This abstract and the presentation materials are available to members only; a login is required.

Join Here